Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new interdisciplinary Oxford research programme will explore the relationship between metabolism and inflammation in metabolic diseases.

Our group will bring expertise in molecular controls of immune cell function. We will use the state-of-the-art genomic technologies to examine the macrophage-neutrophil cross-talk in obesity and the role of the IRF5 pathway by analysing various adipose tissue depots. - Professor Irina Udalova

Led by Professor Robin Choudhury, of the Radcliffe Department of Medicine, the project goes from big data analysis to find a causal relationship between inflammatory factors and the development of type 2 diabetes and related disorders, to analysis of molecular and cellular mechanisms, to intervention studies.

Professor Irina Udalova, from the Kennedy Institute and a research partner on the project says: "Our group will bring expertise in molecular controls of immune cell function. We have recently demonstrated that modulation of a transcription factor IRF5 impacts on the relative mass of different adipose tissue depots and thus insulin sensitivity in obesity. We will use the state-of-the-art genomic technologies to examine the macrophage-neutrophil cross-talk in obesity and the role of the IRF5 pathway by analysing various adipose tissue depots."

This is one of two projects funded by Novo Nordisk Foundation, which combine the fields of immunology and metabolic research and bring together investigators from Oxford, the University of Copenhagen, Denmark, and the Karolinska Institutet in Sweden.

Obesity, insulin resistance, type 2 diabetes (T2D) and associated cardiovascular disease (CVD) - all metabolic diseases - are an epidemic global health problem. Almost 400 million people worldwide have type 2 diabetes, and total deaths from the condition are anticipated to rise by more than 50% in the next 10 years. Therefore, research that addresses the causes and complications of these diseases and delivers effective treatment for them is of paramount importance.

Professor Choudhury says: "The goal of the programme is to revise the way we regard diabetes spectrum diseases by learning more about the role of inflammation in the pathogenesis of the disease and, in particular, the vascular complications. If successful we may open up new therapeutic possibilities that go beyond merely treating blood sugar and instead target biologically relevant pathways and processes."

Similar stories

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.